Join us tomorrow at 8am ET at the Goldman Sachs 45th Annual Global Healthcare conference. We look forward to providing an update on our tarcocimab tedromer, KSI-501 and KSI-101 clinical programs. A live webcast of the presentation will be available here: https://lnkd.in/evfm2VPr
Kodiak Sciences
Biotechnology Research
Palo Alto, California 8,404 followers
We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases.
About us
Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.
- Website
-
http://www.kodiak.com
External link for Kodiak Sciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2009
Locations
-
Primary
Get directions
1200 Page Mill Road
Palo Alto, California 94304, US
Employees at Kodiak Sciences
Updates
-
Today is #ClinicalTrialsDay and in honor of all the investigators and participants in our clinical trials and in others, we want to say thank you! We admire and recognize all that you have done to advance vision care around the world. Learn more about CTD2024 by the Association of Clinical Research Professionals (ACRP) here: https://lnkd.in/e9r9k5Wu
-
-
We continue to progress our late- and early-phase retina pipeline programs. Learn more in our latest press release: https://lnkd.in/emWeNWr3
-
We recently reported fourth quarter and full year 2023 financial results and highlighted important updates about our three clinical programs. Read the full press release here: https://lnkd.in/gm7gZmgQ
-
-
We look forward to kicking off the new year by sharing an update on Kodiak’s clinical pipeline in retina at the 42nd Annual J.P. Morgan Healthcare Conference. Tune in tomorrow at 10:30 am ET. A live webcast of the presentation will be available here: https://lnkd.in/g3MyHiVB
-
We look forward to speaking today at the 6th annual Evercore ISI HealthCONx conference! Tune into the live webcast at 3:25pm EST to learn more about Kodiak’s latest developments: https://lnkd.in/g-w8vFD4
-
-
We reported third quarter 2023 financial results and recent business highlights across the tarcocimab and KSI-501 clinical programs. Learn more here: https://lnkd.in/exdV2a_h
-
-
We are pleased to announce that the primary endpoint and all key secondary endpoints met with high statistical significance in the tarcocimab tedromer Phase 3 diabetic retinopathy GLOW study. We thank the GLOW investigators and patients whose participation and commitment helped us generate this strong data! We look forward to progressing our tarcocimab development program. To learn more, check out our latest press release: https://lnkd.in/gJ5uAifj
-
We look forward to sharing the topline results from the Phase 3 GLOW study at this year’s AAO annual meeting. The GLOW study explores tarcocimab administered in a progressive extended dosing regimen (once every six months) in patients with diabetic retinopathy. For those attending AAO, we hope to see you there! The presentation will also be posted on our IR page concurrently with the start of the presentation: https://lnkd.in/g-w8vFD4